Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

The Johns Hopkins surgeon highlighted rapid growth at the agency, but pledged key staff will have “all the resources they ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

The Trump administration’s plans to reduce NIH grant funding could have long-term consequences for the U.S. drug industry, ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

CBO Abbas Kazimi will replace longtime CEO Jeb Keiper as part of a planned leadership transition at the unorthodox drug ...

Questioned by senators at a Thursday hearing, President Trump's FDA nominee said he would reevaluate which scientific topics ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.